Acute Myocardial Infarction
Conditions
Brief summary
The purpose of this study is to compare p53-induced genes activation as possible markers differentiating between patients presenting with acute myocardial infarction and controls.
Detailed description
The diagnosis of acute myocardial infarction is based on the rise of bio-markers for cardiac necrosis such as troponin. While troponin measurement is highly sensitive for myocardial necrosis it has several limitations that influence its clinical use. First, since the troponin test is reliable only after 4-6 hours from symptoms onset, it has only limited value in the assessment of patients presenting earlier. Second, several clinical situations, most commonly renal dysfunction, are associated with increased troponin level and therefore may decrease the specificity of the test. Third, since troponin rise indicates myocardial infarction it is not useful in the common situations where there is myocardial ischemia without necrosis. The P53 is a tumor suppressing gene activated in different stressful situations including hypoxia. This activation is associated with accelerated transcription (up to 30-50 folds from baseline) of different genes that are involved in apoptosis, DNA repair and in stopping the cell cycle. A study on pregnant women demonstrated high levels of fetal mRNA of these genes in maternal circulation. This gene expression correlated with other signs of fetal stress associated with hypoxia. Myocardial ischemia is another stressful event associated with tissue hypoxia. Nevertheless, the association of this gene expression with myocardial ischemia has not been investigated yet.
Interventions
OTHERBlood test
Blood test
Sponsors
Meir Medical Center
Study design
Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
MALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Acute MI group: Patient presenting with chest pain lasting for at leasY 1 hour and no more than 6 hours accompanied by 1 of the following ECG criteria: * ST segment elevation of anterior or inferior wall (at least 2 consecutive leads) * New LBBB Controls: * Patients undergoing non-invasive evaluation of possible myocardial ischemia
Exclusion criteria
* Chronic lung disease requiring chronic treatment * Any malignancy in the 5 year prior to enrollment
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Expression of P53 induced genes in patients with and without acute myocardial infarction | Up to 4 hours following recruitment |
Secondary
| Measure | Time frame |
|---|---|
| Correlation between P53 associated gene expression with troponin level | After 5 days from recruitment |
Countries
Israel
Outcome results
None listed